The evaluation process for TB drugs involves a series of preclinical and clinical studies. Initially, in vitro studies are conducted using cell cultures to predict a drug's toxicity. These are followed by in vivo studies in animal models to observe the drug's effects in a living organism. Key parameters such as dose-response relationships, target organ toxicity, and potential carcinogenicity are assessed. These studies provide critical data that inform the design of human clinical trials.
